Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Effect of metformin on plasma metabolite profile in the Copenhagen Insulin and Metformin Therapy (CIMT) trial

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Copeptin, a surrogate marker for arginine vasopressin secretion, is positively associated with glucagon

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Mental health in early pregnancy is associated with pregnancy outcome in women with pregestational diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Sertraline in primary care: comments on the PANDA trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  • N Safai
  • T Suvitaival
  • Ali A
  • P Spégel
  • M Al-Majdoub
  • B Carstensen
  • H Vestergaard
  • M Ridderstråle
  • CIMT Trial Group
  • Louise Lundby-Christensen (Member of study group)
  • Lise Tarnow (Member of study group)
  • Birger Thorsteinsson (Member of study group)
  • Christian Gluud (Member of study group)
  • Michael Einar Røder
View graph of relations

AIM: Metformin is the first-line treatment for Type 2 diabetes. However, not all people benefit from this drug. Our aim was to investigate the effects of metformin on the plasma metabolome and whether the pretreatment metabolite profile can predict HbA1c outcome.

METHODS: Post hoc analysis of the Copenhagen Insulin and Metformin Therapy (CMIT) trial, a multicentre study from May 2008 to December 2012, was carried out. We used a non-target method to analyse 87 plasma metabolites in participants with Type 2 diabetes (n = 370) who were randomized in a 1 : 1 ratio to 18 months of metformin or placebo treatment. Metabolites were measured by liquid chromatography-mass spectrometry at baseline and at 18-month follow-up and the data were analysed using a linear mixed-effect model.

RESULTS: At baseline, participants who were on metformin before the trial (n = 312) had higher levels of leucine/isoleucine and five lysophosphatidylethanolamines (LPEs), and lower levels of carnitine and valine compared with metformin-naïve participants (n = 58). At follow-up, participants randomized to metformin (n = 188) had elevated levels of leucine/isoleucine and reduced carnitine, tyrosine and valine compared with placebo (n = 182). At baseline, participants on metformin treatment with the highest levels of carnitine C10:1 and leucine/isoleucine had the lowest HbA1c (P-interaction = 0.02 and 0.03, respectively). This association was not significant with HbA1c at follow-up.

CONCLUSIONS: Metformin treatment is associated with decreased levels of valine, tyrosine and carnitine, and increased levels of leucine/isoleucine. None of the identified metabolites can predict the HbA1c -lowering effect of metformin. Further studies of the association between metformin, carnitine and leucine/isoleucine are warranted. This article is protected by copyright. All rights reserved.

Original languageEnglish
JournalDiabetic Medicine Online
Volume35
Issue number7
Pages (from-to)944-953
Number of pages9
ISSN1464-5491
DOIs
Publication statusPublished - Jul 2018

    Research areas

  • Journal Article

ID: 53618303